Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Häufige urologisch-sexualmedizinische Themen in der Praxis sind das Thema des MMW-Webinars am 5. Juni von 17.30 bis 19 Uhr. Konkret geht es um die Frage, wann bei Harnwegsinfektionen auf Antibiotika verzichtet werden kann, und um ein Update zur Therapie von Libido- und Potenzstörungen des Mannes. Der dritte Vortrag behandelt sexuell übertragbare Krankheiten. Stellen Sie Ihre Fragen an die Experten und sammeln Sie 2 CME-Punkte. Jetzt gleich anmelden!
Erweiterte Suche
Anmelden
nach oben
Current HIV/AIDS Reports
Erschienen in: Current HIV/AIDS Reports 6/2023

23.11.2023

Mpox and HIV—Collision of Two Diseases

verfasst von: Jason Zucker, Aniruddha Hazra, Boghuma K. Titanji

Erschienen in: Current HIV/AIDS Reports | Ausgabe 6/2023

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

The global outbreak of mpox has brought renewed attention to a previously neglected disease which is particularly severe in people with underlying untreated HIV co-infection. For this population, the disease is progressive, severe, and often lethal. In this review, we examine the pathogenesis of mpox disease and its collision with co-existent HIV infection and discuss key considerations for management as well as emerging clinical dilemmas and areas for future research.

Recent Findings

Co-existent untreated HIV infection characterized by severe immunocompromise potentiates the nefarious effects of monkeypox virus infection leading to severe manifestations of mpox. Treating mpox in the context of HIV requires mpox-directed therapies, supportive care, and HIV-specific treatment to restore immune function. Preventative measures for PWH are like those in healthy individuals, but the effectiveness and durability of protection conferred by existing vaccines in PWH remain to be fully characterized.

Summary

Mpox is an important opportunistic infection in PWH. Clinicians should be aware of the unique features of the disease in this population and approaches to care and management of mpox in PWH.
Literatur
1.
2.
Mitjà O, Ogoina D, Titanji BK, Galvan C, Muyembe JJ, Marks M, et al. Monkeypox Lancet. 2023;401(10370):60–74.PubMedCrossRef
3.
•• Mitjà O, Alemany A, Marks M, Lezama Mora JI, Rodríguez-Aldama JC, Torres Silva MS, et al. Mpox in people with advanced HIV infection: a global case series. Lancet. 2023;401(10380):939–49. ()PubMedCrossRef
4.
Govind A, Lazarte SM, Kitchell E, Chow JY, Estelle CD, Fixsen E, et al. Severe mpox infections in people with uncontrolled human immunodeficiency virus. Clin Infect Dis. 2023;76(10):1843–6.PubMedCrossRef
5.
6.
Lansiaux E, Jain N, Laivacuma S, Reinis A. The virology of human monkeypox virus (hMPXV): a brief overview. Virus Res. 2022;322:198932.PubMedCrossRef
7.
Li H, Huang QZ, Zhang H, Liu ZX, Chen XH, Ye LL, et al. The land-scape of immune response to monkeypox virus. EBioMedicine. 2023;87:104424.PubMedCrossRef
8.
Lum FM, Torres-Ruesta A, Tay MZ, Lin RTP, Lye DC, Rénia L, et al. Monkeypox: disease epidemiology, host immunity and clinical interventions. Nat Rev Immunol. 2022;22(10):597–613.PubMedPubMedCentralCrossRef
9.
Song H, Josleyn N, Janosko K, Skinner J, Reeves RK, Cohen M, et al. Monkeypox virus infection of rhesus macaques induces massive expansion of natural killer cells but suppresses natural killer cell functions. PLoS ONE. 2013;8(10):e77804.PubMedPubMedCentralCrossRef
10.
Tarín-Vicente EJ, Alemany A, Agud-Dios M, Ubals M, Suñer C, Antón A, et al. Clinical presentation and virological assessment of confirmed human monkeypox virus cases in Spain: a prospective observational cohort study. The Lancet. 2022;400(10353):661–9.CrossRef
11.
Karem KL, Reynolds M, Hughes C, Braden Z, Nigam P, Crotty S, et al. Monkeypox-induced immunity and failure of childhood smallpox vaccination to provide complete protection. Clin Vaccine Immunol. 2007;14(10):1318–27.PubMedPubMedCentralCrossRef
12.
Nagata N, Saijo M, Kataoka M, Ami Y, Suzaki Y, Sato Y, et al. Pathogenesis of fulminant monkeypox with bacterial sepsis after experimental infection with West African monkeypox virus in a cynomolgus monkey. Int J Clin Exp Pathol. 2014;7(7):4359–70.PubMedPubMedCentral
13.
•• Earl PL, Americo JL, Moss B. Natural killer cells expanded in vivo or ex vivo with IL-15 overcomes the inherent susceptibility of CAST mice to lethal infection with orthopoxviruses. PLoS Pathog. 2020;16(4):1008505. ()CrossRef
14.
Mikulak J, Oriolo F, Zaghi E, Di Vito C, Mavilio D. Natural killer cells in HIV-1 infection and therapy. AIDS. 2017;31(17):2317–30.PubMedCrossRef
15.
16.
McIntosh K, Cherry JD, Benenson AS, Connor JD, Alling DW, Rolfe UT, et al. Clinical and serologic study of four smallpox vaccines comparing variations of dose and route of administration. Standard percutaneous revaccination of children who receive primary percutaneous vaccination. J Infect Dis. 1977;135(1):155–66.PubMedCrossRef
17.
Kempe CH, Bowles C, Meiklejohn G, Berge TO, St Vincent L, Babu BV, et al. The use of vaccinia hyperimmune gamma-globulin in the prophylaxis of smallpox. Bull World Health Organ. 1961;25(1):41–8.PubMedPubMedCentral
18.
19.
20.
•• Edghill-Smith Y, Golding H, Manischewitz J, King LR, Scott D, Bray M, et al. Smallpox vaccine-induced antibodies are necessary and sufficient for protection against monkeypox virus. Nat Med. 2005;11(7):740–7. ()PubMedCrossRef
21.
•• Thornhill JP, Barkati S, Walmsley S, Rockstroh J, Antinori A, Harrison LB, et al. Monkeypox virus infection in humans across 16 countries — April–June 2022. New England J Med. 2022;387(8):679–91. ()CrossRef
22.
23.
Johnston SC, Johnson JC, Stonier SW, Lin KL, Kisalu NK, Hensley LE, et al. Cytokine modulation correlates with severity of monkeypox disease in humans. J Clin Virol. 2015;63:42–5.PubMedCrossRef
24.
Johnson RF, Dyall J, Ragland DR, Huzella L, Byrum R, Jett C, et al. Comparative analysis of monkeypox virus infection of cynomolgus macaques by the intravenous or intrabronchial inoculation route. J Virol. 2011;85(5):2112–25.PubMedCrossRef
25.
O’Shea J, Filardo TD, Morris SB, Weiser J, Petersen B, Brooks JT. Interim guidance for prevention and treatment of monkeypox in persons with HIV infection - United States, August 2022. MMWR Morb Mortal Wkly Rep. 2022;71(32):1023–8.PubMedPubMedCentralCrossRef
26.
Hoffmann C, Jessen H, Wyen C, Grunwald S, Noe S, Teichmann J, et al. Clinical characteristics of monkeypox virus infections among men with and without HIV: a large outbreak cohort in Germany. HIV Med. 2023;24(4):389–97.PubMedCrossRef
27.
Miller MJ, Cash-Goldwasser S, Marx GE, Schrodt CA, Kimball A, Padgett K, et al. Severe monkeypox in hospitalized patients - United States, August 10-October 10, 2022. MMWR Morb Mortal Wkly Rep. 2022;71(44):1412–7.PubMedPubMedCentralCrossRef
28.
Rao AK, Schrodt CA, Minhaj FS, Waltenburg MA, Cash-Goldwasser S, Yu Y, et al. Interim clinical treatment considerations for severe manifestations of mpox - United States, February 2023. MMWR Morb Mortal Wkly Rep. 2023;72(9):232–43.PubMedPubMedCentralCrossRef
29.
Grosenbach DW, Honeychurch K, Rose EA, Chinsangaram J, Frimm A, Maiti B, et al. Oral tecovirimat for the treatment of smallpox. N Engl J Med. 2018;379(1):44–53.PubMedPubMedCentralCrossRef
30.
31.
O’Laughlin K, Tobolowsky FA, Elmor R, Overton R, O’Connor SM, Damon IK, et al. Clinical use of tecovirimat (Tpoxx) for treatment of monkeypox under an investigational new drug protocol - United States, May-August 2022. MMWR Morb Mortal Wkly Rep. 2022;71(37):1190–5.PubMedPubMedCentralCrossRef
32.
McLean J, Stoeckle K, Huang S, Berardi J, Gray B, Glesby MJ, et al. Tecovirimat treatment of people with HIV during the 2022 mpox outbreak : a retrospective cohort study. Ann Intern Med. 2023;176(5):642–8.PubMedPubMedCentralCrossRef
33.
Riser AP, Hanley A, Cima M, Lewis L, Saadeh K, Alarcón J, et al. Epidemiologic and clinical features of mpox-associated deaths - United States, May 10, 2022-March 7, 2023. MMWR Morb Mortal Wkly Rep. 2023;72(15):404–10.PubMedPubMedCentralCrossRef
34.
35.
Stafford A, Rimmer S, Gilchrist M, Sun K, Davies EP, Waddington CS, et al. Use of cidofovir in a patient with severe mpox and uncontrolled HIV infection. Lancet Infect Dis. 2023;23(6):e218–26.PubMedPubMedCentralCrossRef
36.
Raccagni AR, Candela C, Bruzzesi E, Mileto D, Canetti D, Rizzo A, et al. Real-life use of cidofovir for the treatment of severe monkeypox cases. J Med Virol. 2023;95(1):e28218.PubMedCrossRef
37.
Adler H, Gould S, Hine P, Snell LB, Wong W, Houlihan CF, et al. Clinical features and management of human monkeypox: a retrospective observational study in the UK. Lancet Infect Dis. 2022;22(8):1153–62.PubMedPubMedCentralCrossRef
38.
39.
Quenelle DC, Prichard MN, Keith KA, Hruby DE, Jordan R, Painter GR, et al. Synergistic efficacy of the combination of ST-246 with CMX001 against orthopoxviruses. Antimicrob Agents Chemother. 2007;51(11):4118–24.PubMedPubMedCentralCrossRef
40.
Thet AK, Kelly PJ, Kasule SN, Shah AK, Chawala A, Latif A, et al. The use of vaccinia immune globulin in the treatment of severe mpox. Virus infection in human immunodeficiency virus/AIDS. Clin Infect Dis. 2023;76(9):1671–3.PubMedCrossRef
41.
Hyndiuk RA, Seideman S, Leibsohn JM. Treatment of vaccinial keratitis with trifluorothymidine. Arch Ophthalmol. 1976;94(10):1785–6.PubMedCrossRef
42.
Pepose JS, Margolis TP, LaRussa P, Pavan-Langston D. Ocular complications of smallpox vaccination. Am J Ophthalmol. 2003;136(2):343–52.PubMedCrossRef
43.
Cash-Goldwasser S, Labuda SM, McCormick DW, Rao AK, McCollum AM, Petersen BW, et al. Ocular monkeypox - United States, July-September 2022. MMWR Morb Mortal Wkly Rep. 2022;71(42):1343–7.PubMedPubMedCentralCrossRef
44.
Perzia B, Theotoka D, Li K, Moss E, Matesva M, Gill M, et al. Treatment of ocular-involving monkeypox virus with topical trifluridine and oral tecovirimat in the 2022 monkeypox virus outbreak. Am J Ophthalmol Case Rep. 2023;29:101779.PubMedCrossRef
45.
Warner NC, Shishido A, Fulco PP, Sastry S. Immune reconstitution inflammatory syndrome due to monkeypox in two patients with AIDS. AIDS. 2023;37(7):1187–8.PubMedCrossRef
46.
Martinez AE, Frattaroli P, Vu CA, Paniagua L, Mintz J, Bravo-Gonzalez A, Zamudio P, Barco A, Rampersad A, Lichtenberger P, Gonzales-Zamora JA. Successful outcome after treatment with cidofovir, vaccinia, and extended course of tecovirimat in a newly-diagnosed HIV Patient with severe mpox: A case report. Vaccines (Basel). 2023;11(3):650. https://​doi.​org/​10.​3390/​vaccines11030650​.CrossRefPubMed
47.
Yang HS, Li CW, Hsieh FN, Liu CH, Lee JYY, Yang CC. Molluscum contagiosum-associated immune reconstitution inflammatory syndrome in human immunodeficiency virus infection. Dermatologica Sinica. 2016;34(4):196–9.CrossRef
48.
Duraffour S, Lorenzo MM, Zöller G, Topalis D, Grosenbach D, Hruby DE, et al. ST-246 is a key antiviral to inhibit the viral F13L phospholipase, one of the essential proteins for Orthopoxvirus wrapping. J Antimicrob Chemother. 2015;70(5):1367–80.PubMedCrossRef
49.
Garrigues JM, Hemarajata P, Karan A, Shah NK, Alarcón J, Marutani AN, et al. Identification of tecovirimat resistance-associated mutations in human monkeypox virus - Los Angeles county. Antimicrob Agents Chemother. 2023;67(7):e0056823.PubMedCrossRef
50.
Smith TG, Gigante CM, Wynn NT, Matheny A, Davidson W, Yang Y, Condori RE, O’Connell K, Kovar L, Williams TL, Yu YC, Petersen BW, Baird N, Lowe D, Li Y, Satheshkumar PS, Hutson CL. Tecovirimat Resistance in Mpox Patients, United States, 2022-2023. Emerg Infect Dis. 2023;29(12). https://​doi.​org/​10.​3201/​eid2912.​231146.
51.
Overton ET, Stapleton J, Frank I, Hassler S, Goepfert PA, Barker D, et al. Safety and immunogenicity of modified vaccinia Ankara-Bavarian Nordic smallpox vaccine in vaccinia-naive and experienced human immunodeficiency virus-infected individuals: an open-label, controlled clinical phase II trial. Open Forum Infect Dis. 2015;2(2):ofv040.PubMedPubMedCentralCrossRef
52.
Overton ET, Lawrence SJ, Stapleton JT, Weidenthaler H, Schmidt D, Koenen B, et al. A randomized phase II trial to compare safety and immunogenicity of the MVA-BN smallpox vaccine at various doses in adults with a history of AIDS. Vaccine. 2020;38(11):2600–7.PubMedCrossRef
53.
Hazra A, Rusie L, Hedberg T, Schneider JA. Human monkeypox virus infection in the immediate period after receiving modified vaccinia Ankara vaccine. JAMA. 2022;328(20):2064–7.PubMedPubMedCentralCrossRef
54.
Deputy NP, Deckert J, Chard AN, Sandberg N, Moulia DL, Barkley E, et al. Vaccine Effectiveness of JYNNEOS against mpox disease in the United States. N Engl J Med. 2023;388(26):2434–43.PubMedCrossRef
55.
Rosenberg ES, Dorabawila V, Hart-Malloy R, Anderson BJ, Miranda W, O’Donnell T, et al. Effectiveness of JYNNEOS vaccine against diagnosed mpox infection - New York, 2022. MMWR Morb Mortal Wkly Rep. 2023;72(20):559–63.PubMedPubMedCentralCrossRef
56.
Dalton AF, Diallo AO, Chard AN, Moulia DL, Deputy NP, Fothergill A, et al. Estimated effectiveness of JYNNEOS vaccine in preventing mpox: a multijurisdictional case-control study - United States, August 19, 2022-March 31, 2023. MMWR Morb Mortal Wkly Rep. 2023;72(20):553–8.PubMedPubMedCentralCrossRef
57.
Owens LE, Currie DW, Kramarow EA, Siddique S, Swanson M, Carter RJ, et al. JYNNEOS vaccination coverage among persons at risk for mpox - United States, May 22, 2022-January 31, 2023. MMWR Morb Mortal Wkly Rep. 2023;72(13):342–7.PubMedPubMedCentralCrossRef
58.
59.
Keckler MS, Salzer JS, Patel N, Townsend MB, Nakazawa YJ, Doty JB, et al. IMVAMUNE(®) and ACAM2000(®) provide different protection against disease when administered postexposure in an intranasal monkeypox challenge prairie dog model. Vaccines. 2020;8(3):396.PubMedPubMedCentralCrossRef
60.
Massoudi MS, Barker L, Schwartz B. Effectiveness of postexposure vaccination for the prevention of smallpox: results of a Delphi analysis. J Infect Dis. 2003;188(7):973–6.PubMedCrossRef
61.
CDC. Update: multistate outbreak of monkeypox--Illinois, Indiana, Kansas, Missouri, Ohio, and Wisconsin, 2003. MMWR Morb Mortal Wkly Rep. 2003;52(27):642–6.
62.
Luong Nguyen LB, Ghosn J, Durier C, Tachot C, Tartour E, Touati A, et al. A prospective national cohort evaluating ring MVA vaccination as post-exposure prophylaxis for monkeypox. Nat Med. 2022;28(10):1983–4.PubMedCrossRef
63.
Faherty EAG, Holly T, Ogale YP, Crisler G, Becht A, Kern D, et al. Notes from the field: emergence of an mpox cluster primarily affecting persons previously vaccinated against mpox - Chicago, Illinois, March 18-June 12, 2023. MMWR Morb Mortal Wkly Rep. 2023;72(25):696–8.PubMedPubMedCentralCrossRef
64.
Jamard S, Handala L, Faussat C, Vincent N, Stefic K, Gaudy-Graffin C, et al. Resurgence of symptomatic mpox among vaccinated patients: first clues from a new-onset local cluster. Infect Dis Now. 2023;53(4):104714.PubMedPubMedCentralCrossRef
65.
Hazra A, Zucker, J, Bell,, E Flores,J, Gordon L, . Mpox in people with past infection or complete vaccination course: a global case series. 2023. This work describes a global series ofmpox infection in previously vaccinated individuals and individuals with previous mpox infection.
66.
Chastain DB, Motoa G, Ortiz-Martínez Y, Gharamti A, Henao-Martínez AF. Characteristics and clinical manifestations of monkeypox among people with and without HIV in the United States: a retrospective cohort. AIDS. 2023;37(4):611–6.PubMedCrossRef
67.
Patel A, Bilinska J, Tam JCH, Da Silva FD, Mason CY, Daunt A, et al. Clinical features and novel presentations of human monkeypox in a central London centre during the 2022 outbreak: descriptive case series. BMJ. 2022;378:e072410.PubMedPubMedCentralCrossRef
68.
Vivancos-Gallego MJ, Sánchez-Conde M, Rodríguez-Domínguez M, Fernandez-Gonzalez P, Martínez-García L, Garcia-Mouronte E, et al. Human monkeypox in people with HIV: transmission, clinical features, and outcome. Open Forum Infect Dis. 2022;9(11):ofac557.PubMedPubMedCentralCrossRef
69.
Curran KG, Eberly K, Russell OO, Snyder RE, Phillips EK, Tang EC, et al. HIV and sexually transmitted infections among persons with monkeypox - eight U.S. Jurisdictions, May 17-July 22, 2022. MMWR Morb Mortal Wkly Rep. 2022;71(36):1141–7.PubMedPubMedCentralCrossRef
Metadaten
Titel
Mpox and HIV—Collision of Two Diseases
verfasst von
Jason Zucker
Aniruddha Hazra
Boghuma K. Titanji
Publikationsdatum
23.11.2023
Verlag
Springer US
Erschienen in
Current HIV/AIDS Reports / Ausgabe 6/2023
Print ISSN: 1548-3568
Elektronische ISSN: 1548-3576
DOI
https://doi.org/10.1007/s11904-023-00682-w

Weitere Artikel der Ausgabe 6/2023

Current HIV/AIDS Reports 6/2023 Zur Ausgabe

ReviewPaper

Paradata: Measuring Engagement in Digital HIV Interventions for Sexual and Gender Minorities

ReviewPaper

Update on Central Nervous System Effects of the Intersection of HIV-1 and SARS-CoV-2

ReviewPaper

Digital Interventions to Enhance PrEP Uptake and Adherence Through Stigma Reduction

ReviewPaper

Awareness of Heightened Sexual and Behavioral Vulnerability as a Trigger for PrEP Resumption Among Adolescent Girls and Young Women in East and Southern Africa

ReviewPaper

Pharmacological and Behavioral Interventions to Mitigate Premature Aging in Patients with HIV

ReviewPaper

Advancing Diagnosis and Treatment in People Living with HIV and Tuberculosis Meningitis

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

29.05.2024 Larynxkarzinom Nachrichten

Fast ein Viertel der Personen mit mäßig dysplastischen Stimmlippenläsionen entwickelt einen Kehlkopftumor. Solche Personen benötigen daher eine besonders enge ärztliche Überwachung.

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

29.05.2024 Herzinfarkt Nachrichten

Bei Menschen mit Typ-2-Diabetes sind die Chancen, einen Myokardinfarkt zu überleben, in den letzten 15 Jahren deutlich gestiegen – nicht jedoch bei Betroffenen mit Typ 1.

15% bedauern gewählte Blasenkrebs-Therapie

29.05.2024 Urothelkarzinom Nachrichten

Ob Patienten und Patientinnen mit neu diagnostiziertem Blasenkrebs ein Jahr später Bedauern über die Therapieentscheidung empfinden, wird einer Studie aus England zufolge von der Radikalität und dem Erfolg des Eingriffs beeinflusst.

Costims – das nächste heiße Ding in der Krebstherapie?

28.05.2024 Onkologische Immuntherapie Nachrichten

„Kalte“ Tumoren werden heiß – CD28-kostimulatorische Antikörper sollen dies ermöglichen. Am besten könnten diese in Kombination mit BiTEs und Checkpointhemmern wirken. Erste klinische Studien laufen bereits.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise